Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.19 USD
Change Today -0.17 / -0.70%
Volume 128.0K
ACET On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

aceto corp (ACET) Snapshot

Open
$24.38
Previous Close
$24.36
Day High
$24.38
Day Low
$23.81
52 Week High
06/18/15 - $25.97
52 Week Low
08/4/14 - $16.52
Market Cap
704.3M
Average Volume 10 Days
170.3K
EPS TTM
$0.92
Shares Outstanding
29.1M
EX-Date
06/9/15
P/E TM
26.2x
Dividend
$0.24
Dividend Yield
0.99%
Current Stock Chart for ACETO CORP (ACET)

Related News

No related news articles were found.

aceto corp (ACET) Related Businessweek News

No Related Businessweek News Found

aceto corp (ACET) Details

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company operates in three segments: Human Health, Pharmaceutical Ingredients, and Performance Chemicals. The Human Health segment supplies raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. It markets and distributes its generic prescription and over the counter pharmaceutical products to wholesalers, chain drug stores, distributors, and mass market merchandisers. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals, such as antioxidants, photo initiators, catalysts, curatives, brighteners, and adhesion promoters, which make plastics, surface coatings, textiles, fuels, and lubricants; diazos and couplers used in microfilms and blueprints, as well as in the photo tooling of printed circuit boards; and organic intermediates and colorants. Its raw materials are also used in electronic parts and binders. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitors for potatoes. The company serves various companies in the industrial chemical, agricultural, and human health and pharmaceutical industries primarily in the United States, Europe, and Asia. Aceto Corporation was founded in 1947 and is headquartered in Port Washington, New York.

270 Employees
Last Reported Date: 09/5/14
Founded in 1947

aceto corp (ACET) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $563.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $341.3K
President of Rising Pharmaceuticals and Chief...
Total Annual Compensation: $338.5K
Senior Vice President of Business Development
Total Annual Compensation: $309.5K
Senior Vice President of Corporate Business D...
Total Annual Compensation: $304.4K
Compensation as of Fiscal Year 2014.

aceto corp (ACET) Key Developments

Aceto Corporation Enters into Amendment No. 1 to its Credit Agreement

On June 25, 2015, Aceto Corporation entered into Amendment No. 1 to its Credit Agreement, dated as of April 30, 2014, with the lenders which from time to time are parties to the Amended Credit Agreement, JPMorgan Chase Bank, N.A., as administrative agent for the Lenders and Wells Fargo Bank, National Association as Syndication Agent. The Amended Credit Agreement includes the following changes: Increases the aggregate revolving commitment under the existing credit facility from $60 million to $75 million.

Aceto Corp. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 01:30 PM

Aceto Corp. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Salvatore J. Guccione, Chief Executive Officer, President and Director.

Aceto Corp. Announces Consolidated Unaudited Earnings Results for Third Quarter and Nine Months Ended March 31, 2015; Provides Earnings Guidance for the Fourth Quarter and Full Year of 2015

Aceto Corp. announced consolidated unaudited earnings results for third quarter and nine months ended March 31, 2015. For the quarter, the company reported net sales of $145,796,000, operating income of $15,430,000, income before income taxes of $13,626,000, net income of $8,411,000 or $0.29 diluted per share compared to net sales of $124,830,000, operating income of $7,078,000, income before income taxes of $7,904,000, net income of $5,356,000 or $0.19 diluted per share for the same quarter a year ago. Adjusted net income was $10,041,000 or $0.34 diluted per share against $6,887,000 or $0.24 diluted per share for the same quarter a year ago. EBITDA for the third quarter was $17.5 million an increase of $7.4 million or 73% over the prior year period. On a constant-currency basis, revenue has been negatively affected by approximately 2%, and its diluted earnings per share by approximately 5%. For the year to date, the company reported net sales of $400,364,000, operating income of $34,725,000, income before income taxes of $31,756,000, net income of $19,847,000 or $0.68 diluted per share compared to net sales of $370,599,000, operating income of $35,237,000, income before income taxes of $36,208,000, net income of $23,446,000 or $0.82 diluted per share for the same period a year ago. Adjusted net income was $24,868,000 or $0.85 diluted per share against $27,148,000 or $0.95 diluted per share for the same quarter a year ago. The company continues to expect the fourth quarter to be the high quarterly contributor to net income and earnings per share for fiscal 2015. On a constant currency basis, the company continue to expect sales and earnings per share growth for fiscal 2015 to be in the mid-to-upper single digit range, despite the slowness in new product approvals and nutritionals. However, on a reported basis, company now expect sales and earnings per share growth to be in the mid-single digit range for fiscal 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACET:US $24.19 USD -0.17

ACET Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Vanguard Corp $12.92 USD -0.75
Calgon Carbon Corp $19.01 USD -0.20
Hawkins Inc $40.00 USD -0.49
KMG Chemicals Inc $24.48 USD -0.36
Quaker Chemical Corp $85.70 USD -2.31
View Industry Companies
 

Industry Analysis

ACET

Industry Average

Valuation ACET Industry Range
Price/Earnings 27.7x
Price/Sales 1.3x
Price/Book 2.9x
Price/Cash Flow 27.7x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACETO CORP, please visit www.aceto.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.